Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre

Scientific Reports

Volumn 9, Issue 1, 2019, Pages

  Jermini, Mégane ^a,e   Dubois, Julie ^b,c   Rodondi, Pierre Yves ^b,c   Zaman, Khalil ^d   Buclin, Thierry ^d   Csajka, Chantal ^d,e   Orcurto, Angela ^d   E Rothuizen, Laura ^d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF FRIBOURG   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ALTERNATIVE MEDICINE; CHEMISTRY; CROSS-SECTIONAL STUDY; DIETARY SUPPLEMENT; FEMALE; HERB DRUG INTERACTION; HUMAN; MALE; MEDICINAL PLANT; MIDDLE AGED; NEOPLASM; PROCEDURES; TEA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMPLEMENTARY THERAPIES; CROSS-SECTIONAL STUDIES; DIETARY SUPPLEMENTS; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLANTS, MEDICINAL; TEA; YOUNG ADULT;

EID: 85063432815     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-019-41532-3     Document Type: Article

References (51)

1. Eisenberg, D. M. et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. Jama 280, 1569–1575 (1998).
2. Clarke, T. C., Black, L. I., Stussman, B. J., Barnes, P. M. & Nahin, R. L. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl Health Stat Report, 1–16 (2015).
3. Eardley, S. et al. A systematic literature review of complementary and alternative medicine prevalence in EU. Forschende Komplementarmedizin (2006) 19(Suppl 2), 18–28, 10.1159/000342708 (2012).
4. Klein, S. D., Torchetti, L., Frei-Erb, M. & Wolf, U. Usage of Complementary Medicine in Switzerland: Results of the Swiss Health Survey 2012 and Development Since 2007. PloS one 10, e0141985, 10.1371/journal.pone.0141985 (2015).
5. Molassiotis, A. et al. Use of complementary and alternative medicine in cancer patients: a European survey. Annals of oncology: official journal of the European Society for Medical Oncology 16, 655–663, 10.1093/annonc/mdi110 (2005).
6. Tascilar, M., de Jong, F. A., Verweij, J. & Mathijssen, R. H. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 11, 732–741, 10.1634/theoncologist.11-7-732 (2006).
7. van der Weg, F. & Streuli, R. A. Use of alternative medicine by patients with cancer in a rural area of Switzerland. Swiss medical weekly 133, 233–240, doi:2003/15/smw-10160 (2003).
8. Inglin, S., Amsler, S., Jeangros, C., Pargoux-Vallade, C. & Sappino, A.-P. Evaluation du recours aux médecines complémentaires chez les patients en suivi oncologique. Revue médicale suisse: revue officielle de la Société médicale de la Suisse romande et de la Société suisse de médecine interne (2008).
9. Werneke, U. et al. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 90, 408–413, 10.1038/sj.bjc.6601560 (2004).
10. Salamonsen, A. Mind the gap! Lay and medical perceptions of risks associated with the use of alternative treatment and conventional medicine. Forschende Komplementarmedizin (2006) 22, 24–29, 10.1159/000376555 (2015).
11. Medicine, I. O. Complementary and Alternative Medicine in the United States. (The National Academies Press, 2005).
12. Frenkel, M. et al. Integrating dietary supplements into cancer care. Integrative cancer therapies 12, 369–384, 10.1177/1534735412473642 (2013).
13. Timbo, B. B., Ross, M. P., McCarthy, P. V. & Lin, C. T. Dietary supplements in a national survey: Prevalence of use and reports of adverse events. Journal of the American Dietetic Association 106, 1966–1974, 10.1016/j.jada.2006.09.002 (2006).
14. Chang, K. H., Brodie, R., Choong, M. A., Sweeney, K. J. & Kerin, M. J. Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals. BMC Cancer 11, 196, 10.1186/1471-2407-11-196 (2011).
15. De Smet, P. A. Health risks of herbal remedies: an update. Clinical pharmacology and therapeutics 76, 1–17, 10.1016/j.clpt.2004.03.005 (2004).
16. Niggemann, B. & Gruber, C. Side-effects of complementary and alternative medicine. Allergy 58, 707–716, 10.1034/j.1398-9995.2003.00219.x (2003).
17. Olaku, O. & White, J. D. Herbal therapy use by cancer patients: a literature review on case reports. European journal of cancer 47, 508–514, 10.1016/j.ejca.2010.11.018 (2011).
18. Sparreboom, A., Cox, M. C., Acharya, M. R. & Figg, W. D. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22, 2489–2503, 10.1200/JCO.2004.08.182 (2004).
19. McLay, J. S., Stewart, D., George, J., Rore, C. & Heys, S. D. Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? European journal of clinical pharmacology 68, 811–819, 10.1007/s00228-011-1181-6 (2012).
20. Haefeli, W. E. & Carls, A. Drug interactions with phytotherapeutics in oncology. Expert opinion on drug metabolism & toxicology 10, 359–377, 10.1517/17425255.2014.873786 (2014).
21. Meijerman, I., Beijnen, J. H. & Schellens, J. H. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 11, 742–752, 10.1634/theoncologist.11-7-742 (2006).
22. Posadzki, P., Watson, L. & Ernst, E. Herb-drug interactions: an overview of systematic reviews. Br J Clin Pharmacol 75, 603–618, 10.1111/j.1365-2125.2012.04350.x (2013).
23. Caraci, F., Crupi, R., Drago, F. & Spina, E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 12, 570–577 (2011).
24. Clarke, S. J. & McLachlan, A. J. Interaction between Complementary and Alternate Medicine with Conventional Anti-cancer Medicine. Cancer Forum 35, 18–23 (2011).
25. Bonacchi, A. et al. Use and perceived benefits of complementary therapies by cancer patients receiving conventional treatment in Italy. Journal of pain and symptom management 47, 26–34, 10.1016/j.jpainsymman.2013.03.014 (2014).
26. Huebner, J. et al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer research 34, 943–948 (2014).
27. Paul, M. et al. Patients with advanced cancer and their usage of complementary and alternative medicine. Journal of cancer research and clinical oncology 139, 1515–1522, 10.1007/s00432-013-1460-y (2013).
28. Horneber, M. et al. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integrative cancer therapies 11, 187–203, 10.1177/1534735411423920 (2012).
29. Ramos-Esquivel, A., Viquez-Jaikel, A. & Fernandez, C. Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer: A Prospective Study of Medication Surveillance. J Oncol Pract 13, e613–e622, 10.1200/JOP.2017.020859 (2017).
30. Patterson, R. E. et al. Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. Journal of alternative and complementary medicine (New York, N.Y.) 8, 477–485, 10.1089/107555302760253676 (2002).
31. Gansler, T., Kaw, C., Crammer, C. & Smith, T. A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer 113, 1048–1057, 10.1002/cncr.23659 (2008).
32. Forester, S. C. & Lambert, J. D. The role of antioxidant versus pro-oxidant effects of green tea polyphenols in cancer prevention. Mol Nutr Food Res 55, 844–854, 10.1002/mnfr.201000641 (2011).
33. Du, G. J. et al. Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients 4, 1679–1691, 10.3390/nu4111679 (2012).
34. Golden, E. B. et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors. Blood 113, 5927 (2009).
35. Yates, J. S. et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 13, 806–811, 10.1007/s00520-004-0770-7 (2005).
36. Loquai, C. et al. Use of complementary and alternative medicine: A multicenter cross-sectional study in 1089 melanoma patients. European journal of cancer 71, 70–79, 10.1016/j.ejca.2016.10.029 (2017).
37. Ernst, E. Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ 78, 252–257 (2000).
38. Frenkel, M. & Cohen, L. Effective communication about the use of complementary and integrative medicine in cancer care. Journal of alternative and complementary medicine (New York, N.Y.) 20, 12–18, 10.1089/acm.2012.0533 (2014).
39. Hubner, J. et al. Counseling cancer patients on complementary and alternative medicine. Background, theory, and implementation of nationwide counseling facilities. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft.. [et al] 189, 613–617, 10.1007/s00066-013-0392-4 (2013).
40. Berretta, M. et al. Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey. Oncotarget 8, 24401–24414, 10.18632/oncotarget.14224 (2017).
41. Lee, R. T. et al. National survey of US oncologists’ knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol 32, 4095–4101, 10.1200/JCO.2014.55.8676 (2014).
42. Ben-Arye, E. et al. Potential risks associated with traditional herbal medicine use in cancer care: A study of Middle Eastern oncology health care professionals. Cancer 122, 598–610, 10.1002/cncr.29796 (2016).
43. Chen, M., Zhou, S. Y., Fabriaga, E., Zhang, P. H. & Zhou, Q. Food-drug interactions precipitated by fruit juices other than grapefruit juice: An update review. J Food Drug Anal 26, S61–S71, 10.1016/j.jfda.2018.01.009 (2018).
44. Mouly, S., Lloret-Linares, C., Sellier, P. O., Sene, D. & Bergmann, J. F. Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John’s Wort? Pharmacol Res 118, 82–92, 10.1016/j.phrs.2016.09.038 (2017).
45. Goey, A. K., Mooiman, K. D., Beijnen, J. H., Schellens, J. H. & Meijerman, I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer treatment reviews 39, 773–783, 10.1016/j.ctrv.2012.12.008 (2013).
46. Hermann, R. & von Richter, O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta medica 78, 1458–1477, 10.1055/s-0032-1315117 (2012).
47. Shi, S. & Klotz, U. Drug interactions with herbal medicines. Clinical pharmacokinetics 51, 77–104, 10.2165/11597910-000000000-00000 (2012).
48. Aveni, E. et al. The Attitudes of Physicians, Nurses, Physical Therapists, and Midwives Toward Complementary Medicine for Chronic Pain: A Survey at an Academic. Hospital. Explore 12, 341–346, 10.1016/j.explore.2016.06.001 (2016).
49. Foley, H., Steel, A., Cramer, H., Wardle, J. & Adams, J. Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis. Scientific Reports 9, 1573, 10.1038/s41598-018-38279-8 (2019).
50. Katzung, B. G. Pharmacologie fondamentale et clinique. (Piccin, 2006).
51. Goodman, L. S., Gilman, A., Brunton, L. L., Lazo, J. S. & Parker, K. L. Goodman & Gilman’s the pharmacological basis of therapeutics. (McGraw-Hill, 2006).